Opinion

Video

The Value of Multidisciplinary Care in PSMA-PET Imaging

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

Experts on prostate cancer discuss the benefits to multidisciplinary care as it pertains to PSMA-PET imaging.

Current Time 0:00
Duration 6:37
Loaded: 0%
Stream Type LIVE
Remaining Time 6:37
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
    Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
    Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
    Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
    1 expert in this video
    Using Ultrasensitive PSA Assays in Routine Practice
    1 expert in this video
    Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    1 expert in this video
    Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
    1 expert in this video
    Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Related Content
    Amy L. Shaver, PhD, PharmD, MPH
    June 5th 2025

    GLP-1 agonist use is rising in men with prostate cancer

    Benjamin P. Saylor
    In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Rana R. McKay, MD, FASCO
    June 4th 2025

    COMRADE: Olaparib plus radium-223 improves rPFS in mCRPC

    Benjamin P. Saylor
    “This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Michael Ong, MD
    June 3rd 2025

    Subgroup analysis evaluates darolutamide in previously treated mCRPC

    Benjamin P. Saylor
    Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.
    Alicia Morgans, MD, MPH
    June 3rd 2025

    Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

    Benjamin P. Saylor
    “As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
    © 2025 MJH Life Sciences

    All rights reserved.